Patient characteristics
| . | All patients . | no del(13q) . | del(13q) . | no t(4;14) . | no t(4;14) matched pair . | t(4;14) . | no del(17p13) . | del(17p13) . |
|---|---|---|---|---|---|---|---|---|
| Patients, n (%) | 130 (100.0) | 76 (58.5) | 54 (41.5) | 102 (78.5) | 28 | 28 (21.5) | 118 (90.8) | 12 (9.2) |
| Median age, y (range) | 61 (31-84) | 61 (31-84) | 60 (41-81) | 62 (31-84) | 64 (44-84) | 60 (47-81) | 61 (31-84) | 61 (47-76) |
| Median time from diagnosis, y (range) | 3.45 (0.16-11.61) | 3.57 (0.16-11.61) | 3.04 (0.63-11.36) | 3.72 (0.17-11.61) | 2.43 (0.17-5.09) | 2.52 (0.16-7.40) | 3.63 (0.16-11.61) | 1.84 (0.95-7.65) |
| International Staging System, % | ||||||||
| I | 35.9 | 40.8 | 29.6 | 37.2 | 14.2 | 32.1 | 37.3 | 25.0 |
| II | 35.1 | 30.3 | 42.6 | 33.4 | 78.6 | 46.4 | 33.1 | 58.3 |
| III | 19.8 | 21.1 | 18.5 | 22.5 | 7.2 | 10.7 | 20.3 | 16.7 |
| Missing | 9.2 | 7.8 | 9.3 | 6.9 | 0.0 | 10.8 | 9.3 | 0.0 |
| Median serum creatinine, μmol/L, median (range) | 96 (43-406) | 95 (47-347) | 97 (43-406) | 96 (43-406) | 100 (47-200) | 94 (44-347) | 96 (45-406) | 88.5 (43-292) |
| Median β2-microglobulin level, mg/L (range) | 3.13 (1.1-16.8) | 3.0 (1.1-16.8) | 3.34 (1.3-11.0) | 2.9 (1.1-16.8) | 3.4 (1.1-7.15) | 3.31 (1.5-8.6) | 2.9 (1.1-16.8) | 3.88 (1.5-6.7) |
| β2 level > 4 mg/L, n (%) | 30 (23.1) | 21 (27.6) | 21 (38.9) | 32 (31.4) | 6 (21.5) | 10 (35.7) | 36 (30.5) | 6 (50.0) |
| Median serum albumin level, g/L (range) | 38.0 (12-48.3) | 39.0 (12-48.3) | 36.0 (21-47) | 38.0 (12-48.3) | 34 (22-47.9) | 35.5 (21-46) | 38.0 (19-48.3) | 32.0 (12-46) |
| Albumin ≥ 35 g/L, n (%) | 85 (65.4) | 54 (71.1) | 31 (57.4) | 70 (68.6) | 11 (39.3) | 15 (53.6) | 80 (67.8) | 5 (41.7) |
| Median no. of prior therapies | 2 (1-6) | 2 (1-6) | 2.5 (1-6) | 3 (1-6) | 2 (1-4) | 2 (1-6) | 2 (1-6) | 3 (1-6) |
| 3 or more therapies, % | 49.2 | 48.7 | 50.0 | 52.9 | 35.7 | 35.7 | 46.6 | 75.0 |
| Thalidomide, % | 53.8 | 51.3 | 57.4 | 54.9 | 39.3 | 50.0 | 52.5 | 66.7 |
| Bortezomib, % | 45.4 | 47.4 | 42.6 | 48.0 | 35.7 | 35.7 | 44.9 | 50.0 |
| Stem cell transplantation, % | 72.3 | 75 | 68.5 | 74.5 | 60.7 | 64.3 | 72.0 | 75.0 |
| FISH studies, % | ||||||||
| del(13q), % | 41.5 | 0 | 100 | 34.3 | 39.3 | 67.9 | 38.1 | 75.0 |
| t(4;14), % | 21.5 | 11.8 | 35.2 | 0 | 0 | 100 | 21.2 | 25.0 |
| del(17p13), % | 9.2 | 3.9 | 16.6 | 8.8 | 10.7 | 10.7 | 0 | 100 |
| . | All patients . | no del(13q) . | del(13q) . | no t(4;14) . | no t(4;14) matched pair . | t(4;14) . | no del(17p13) . | del(17p13) . |
|---|---|---|---|---|---|---|---|---|
| Patients, n (%) | 130 (100.0) | 76 (58.5) | 54 (41.5) | 102 (78.5) | 28 | 28 (21.5) | 118 (90.8) | 12 (9.2) |
| Median age, y (range) | 61 (31-84) | 61 (31-84) | 60 (41-81) | 62 (31-84) | 64 (44-84) | 60 (47-81) | 61 (31-84) | 61 (47-76) |
| Median time from diagnosis, y (range) | 3.45 (0.16-11.61) | 3.57 (0.16-11.61) | 3.04 (0.63-11.36) | 3.72 (0.17-11.61) | 2.43 (0.17-5.09) | 2.52 (0.16-7.40) | 3.63 (0.16-11.61) | 1.84 (0.95-7.65) |
| International Staging System, % | ||||||||
| I | 35.9 | 40.8 | 29.6 | 37.2 | 14.2 | 32.1 | 37.3 | 25.0 |
| II | 35.1 | 30.3 | 42.6 | 33.4 | 78.6 | 46.4 | 33.1 | 58.3 |
| III | 19.8 | 21.1 | 18.5 | 22.5 | 7.2 | 10.7 | 20.3 | 16.7 |
| Missing | 9.2 | 7.8 | 9.3 | 6.9 | 0.0 | 10.8 | 9.3 | 0.0 |
| Median serum creatinine, μmol/L, median (range) | 96 (43-406) | 95 (47-347) | 97 (43-406) | 96 (43-406) | 100 (47-200) | 94 (44-347) | 96 (45-406) | 88.5 (43-292) |
| Median β2-microglobulin level, mg/L (range) | 3.13 (1.1-16.8) | 3.0 (1.1-16.8) | 3.34 (1.3-11.0) | 2.9 (1.1-16.8) | 3.4 (1.1-7.15) | 3.31 (1.5-8.6) | 2.9 (1.1-16.8) | 3.88 (1.5-6.7) |
| β2 level > 4 mg/L, n (%) | 30 (23.1) | 21 (27.6) | 21 (38.9) | 32 (31.4) | 6 (21.5) | 10 (35.7) | 36 (30.5) | 6 (50.0) |
| Median serum albumin level, g/L (range) | 38.0 (12-48.3) | 39.0 (12-48.3) | 36.0 (21-47) | 38.0 (12-48.3) | 34 (22-47.9) | 35.5 (21-46) | 38.0 (19-48.3) | 32.0 (12-46) |
| Albumin ≥ 35 g/L, n (%) | 85 (65.4) | 54 (71.1) | 31 (57.4) | 70 (68.6) | 11 (39.3) | 15 (53.6) | 80 (67.8) | 5 (41.7) |
| Median no. of prior therapies | 2 (1-6) | 2 (1-6) | 2.5 (1-6) | 3 (1-6) | 2 (1-4) | 2 (1-6) | 2 (1-6) | 3 (1-6) |
| 3 or more therapies, % | 49.2 | 48.7 | 50.0 | 52.9 | 35.7 | 35.7 | 46.6 | 75.0 |
| Thalidomide, % | 53.8 | 51.3 | 57.4 | 54.9 | 39.3 | 50.0 | 52.5 | 66.7 |
| Bortezomib, % | 45.4 | 47.4 | 42.6 | 48.0 | 35.7 | 35.7 | 44.9 | 50.0 |
| Stem cell transplantation, % | 72.3 | 75 | 68.5 | 74.5 | 60.7 | 64.3 | 72.0 | 75.0 |
| FISH studies, % | ||||||||
| del(13q), % | 41.5 | 0 | 100 | 34.3 | 39.3 | 67.9 | 38.1 | 75.0 |
| t(4;14), % | 21.5 | 11.8 | 35.2 | 0 | 0 | 100 | 21.2 | 25.0 |
| del(17p13), % | 9.2 | 3.9 | 16.6 | 8.8 | 10.7 | 10.7 | 0 | 100 |